Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Techno DrugsDHA:TECHNODRUG -1.62%37 EBIT per Share is BDT5.24 as of Mar. 2026. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 10 warning signs investors should review. Among 813 Drug Manufacturers companies, Techno Drugs ranks worse than 123001.11% on this metric.
Techno Drugs's EBIT per Share for the
three
months ended in Mar. 2026 was BDT1.05.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was BDT5.24.
During the past 12 months, the average EBIT per Share Growth Rate of Techno Drugs was 17.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Techno Drugs's EBIT per Share or its related term are showing as below:
DHA:TECHNODRUG's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.5 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Techno Drugs's EBIT for the
three
months ended in Mar. 2026 was BDT139 Mil.
Techno Drugs (DHA:TECHNODRUG) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Techno Drugs EBIT per Share Related Terms
Techno Drugs EBIT per Share Historical Data
* Premium members only.
The historical data trend for Techno Drugs's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT5.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Techno Drugs (DHA:TECHNODRUG) has a EBIT per Share of BDT5.24 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Techno Drugs and its competitors. According to the industry distribution chart, Techno Drugs ranks #999999 out of 813 companies in the Drug Manufacturers industry.
Is Techno Drugs' EBIT per Share too high?
Techno Drugs' current EBIT per Share is BDT5.24. Based on the distribution chart, Techno Drugs ranks #999999 out of 813 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Techno Drugs ranks #999999 out of 813 companies for EBIT per Share. This places Techno Drugs in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Techno Drugs and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Techno Drugs's current EBIT per Share is BDT5.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current EBIT per Share of BDT5.24. The current EBIT per Share is BDT5.24. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current EBIT per Share is BDT5.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score
Get the complete analysis for DHA:TECHNODRUG
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:TECHNODRUG has been successfully added to your 
